Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

Italian pharmaceutical company Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for approximately $4.1 billion USD ($3.5 billion EUR). The deal strengthens Angelini Pharma's global presence in brain health and rare diseases while expanding into the U.S. market. Blackstone will invest €1 billion in preferred equity, and CDP Equity will acquire a 23.5% stake in Angelini Pharma for approximately €1 billion.